Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer



Page Path
HOME > J Liver Cancer > Volume 16(1); 2016 > Article
Review Article Treatments Other than Sorafenib for Patients with Advanced Hepatocellular Carcinoma
Do Seon Song, Si Hyun Bae
Journal of Liver Cancer 2016;16(1):1-6
Published online: March 31, 2016
Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
  • 17 Download
  • 1 Crossref
  • 0 Scopus

Sorafenib is the standard treatment for advanced hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer staging system. However, because of its unsatisfactory efficacy, adverse effects, and high cost, the use of sorafenib is limited, and other treatment modalities are required. Recent studies reported that treatment modalities other than sorafenib, such as hepatic arterial infusion chemotherapy and transarterial radioembolization, showed comparable or better response rates and survival rates than sorafenib. In this review, treatment modalities that could be used as alternatives to sorafenib will be discussed. (J Liver Cancer 2016;16:1-6)

JLC : Journal of Liver Cancer